Processa Pharmaceuticals reported a significant net loss of $189.8 million for the nine months ended September 30, 2026, primarily driven by a $178.0 million charge for acquired in-process research and development following the acquisition of Vidya Therapeutics. The company significantly strengthened its liquidity position during the period, ending with $180.2 million in cash and cash equivalents following a $200.0 million private placement financing.
Processa Pharmaceuticals issued a stockholder letter outlining its strategic shift toward immunological and inflammatory (I&I) diseases following its July acquisition of Vidya Therapeutics. The company highlighted the advancement of its lead BTK inhibitor candidate, VT-7208, into Phase 2 development for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis, supported by approximately $183.3 million in net cash proceeds.
Processa Pharmaceuticals appointed Gregory J. Flesher as Chief Operating Officer, effective November 4, 2026. Mr. Flesher will receive an annual base salary of $700,000, a target bonus of up to 60%, and an initial stock option grant representing 3.0% of the company's fully-diluted capital stock, contingent on shareholder approval of a new equity incentive plan.
Processa Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for VT-7208, allowing the company to initiate a Phase 2 study in patients with chronic spontaneous urticaria. The company also appointed Dr. Sheila Gujrathi as Executive Chair and entered into a research collaboration with Generian Pharmaceuticals to expand its pipeline.
Processa Pharmaceuticals M&A Deal with Vidya Therapeutics, Inc.
Processa Pharmaceuticals filed an amendment to its 8-K to provide audited financial statements and pro forma information following its acquisition of Vidya Therapeutics. The deal adds VT7208, a CNS-penetrant BTK inhibitor, to Processa's pipeline for the treatment of autoimmune conditions like multiple sclerosis and food allergies.